Featured Research

from universities, journals, and other organizations

Cottonseed-based Drug Shows Promise In Treating Severe Brain Cancer

Date:
May 29, 2009
Source:
University of Alabama at Birmingham
Summary:
An experimental compound showed good results for months in patients with glioblastoma multiforme, researchers say. After undergoing other treatments, including surgery, chemotherapy and radiation, the trial patients' brain cancer had begun to grow again prior to starting on the current clinical trial.

An experimental drug derived from cottonseeds shows promise in treating the recurrence of glioblastoma multiforme, widely considered the most lethal brain cancer, said researchers at the University of Alabama at Birmingham (UAB).

Related Articles


The new results are from a Phase II clinical trial of AT-101, a pill manufactured from a potent compound in cottonseeds that overcomes the abnormal growth patterns of tumor cells. This cottonseed-based agent must be properly dosed and monitored by physicians.

In clinical tests, AT-101 halted the cancer's progression in many of the 56 patients, said John Fiveash, M.D., an associate professor in the UAB Department of Radiation Oncology and the lead researcher on the new study.

Despite undergoing other treatments, including surgery, chemotherapy and radiation, the trial patients' brain cancer had begun to grow again prior to starting AT-101 treatments. The trial-monitored patients took only AT-101 daily for three out of four weeks. Glioblastomas are more common in adults and are considered fast-growing brain tumors that are very difficult to treat, Fiveash said.

"After getting this drug some of these patients went many months without any new growth in their tumors," Fiveash said. "We are able to do that with a well-tolerated oral medication, and that is a major benefit." His initial results will be presented May 30 during the poster discussion of central nervous system tumors at the American Society for Clinical Oncology annual meeting in Orlando, Fla.

Fiveash said the drug would likely work best in combination with radiation and chemotherapy to boost the cancer-fighting properties of those treatments. Also, investigators are trying to learn which patients are most likely to benefit from AT-101.

The AT-101 trial is a partnership that includes Fiveash, the UAB Comprehensive Cancer Center, Massachusetts General Hospital in Boston, Johns Hopkins University in Baltimore, The Cleveland Clinic in Ohio, Henry Ford Hospital in Detroit, Emory University in Atlanta, Moffit Cancer Center in Tampa, the University of Pennsylvania in Philadelphia, Wake Forest University in Winston-Salem, N.C., and the National Cancer Institute's Cancer Therapeutics Evaluation Program.

AT 101 is manufactured by Ascenta Therapeutics Inc. based in Malvern, Penn. Multiple preclinical and clinical trials with AT-101 are ongoing in several tumor types, including prostate, lung, B-cell malignancies and other forms of cancer.


Story Source:

The above story is based on materials provided by University of Alabama at Birmingham. Note: Materials may be edited for content and length.


Cite This Page:

University of Alabama at Birmingham. "Cottonseed-based Drug Shows Promise In Treating Severe Brain Cancer." ScienceDaily. ScienceDaily, 29 May 2009. <www.sciencedaily.com/releases/2009/05/090528110621.htm>.
University of Alabama at Birmingham. (2009, May 29). Cottonseed-based Drug Shows Promise In Treating Severe Brain Cancer. ScienceDaily. Retrieved March 2, 2015 from www.sciencedaily.com/releases/2009/05/090528110621.htm
University of Alabama at Birmingham. "Cottonseed-based Drug Shows Promise In Treating Severe Brain Cancer." ScienceDaily. www.sciencedaily.com/releases/2009/05/090528110621.htm (accessed March 2, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, March 2, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Treadmill Test Can Predict Chance Of Death Within A Decade

Treadmill Test Can Predict Chance Of Death Within A Decade

Newsy (Mar. 2, 2015) Johns Hopkins researchers analyzed 58,000 heart stress tests to come up with a formula that predicts a person&apos;s chances of dying in the next decade. Video provided by Newsy
Powered by NewsLook.com
GlaxoSmithKline and Novartis Try Swapping Success

GlaxoSmithKline and Novartis Try Swapping Success

Reuters - Business Video Online (Mar. 2, 2015) GlaxoSmithKline and Novartis have completed a series of asset swaps worth more than $20 billion. As Grace Pascoe reports they say the deal will reshape both drugmakers. Video provided by Reuters
Powered by NewsLook.com
How Can West Africa Rebuild After Ebola?

How Can West Africa Rebuild After Ebola?

Reuters - Business Video Online (Mar. 2, 2015) How best to rebuild the three West African countries struggling with Ebola will be discussed in Brussels this week. As Hayley Platt reports Sierra Leone has the toughest job ahead - its once thriving economy has been ravaged by the disease. Video provided by Reuters
Powered by NewsLook.com
Doctors Often Give In To Vaccine-Wary Parents

Doctors Often Give In To Vaccine-Wary Parents

Newsy (Mar. 2, 2015) A new survey published in the journal Pediatrics found many doctors are giving in to parents&apos; requests to delay vaccinating their children. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins